Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318966 | 0.70 | — | — | |
| SCHEMBL4924782 | 0.69 | — | — | |
| SCHEMBL6661278 | 0.67 | — | — | |
| SCHEMBL3337255 | 0.67 | — | — | |
| SCHEMBL4922063 | 0.67 | — | — | |
| SCHEMBL8941078 | 0.67 | — | — | |
| SCHEMBL4927303 | 0.64 | — | — | |
| SCHEMBL1637915 | 0.64 | — | — | |
| SCHEMBL491561 | 0.64 | CYP1A2 (0.34) | — | |
| SCHEMBL7585956 | 0.63 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329667-B2 | A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | claimed |
| US-7273871-B2 | Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists | SB PHARMCO PUERTO RICO INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1341793-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2007-01-17 | — | — | EP | claimed |
| EP-1383498-B1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-03-15 | — | — | EP | claimed |
| EP-1425281-B1 | Tricyclic CRF receptor antagonists | SB PHARMCO PUERTO RICO INC CSC (PR) | 2006-02-01 | — | — | EP | claimed |
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-30 | — | — | US | claimed |
| US-20040242623-A1 | Chemical compounds | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2004-12-02 | — | — | US | claimed |
| US-20040235871-A1 | Crf receptor antagonists | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | claimed |
| US-20040229879-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-11-18 | — | — | US | claimed |
| CN-1541217-A | Chemical compounds | SBҩ�ﲨ�������˾ | 2004-10-27 | — | — | CN | claimed |
| EP-1129091-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2002-10-02 | — | — | EP | claimed |
| WO-2002040480-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| US-6348466-B1 | HETEROCYCLIC RECEPTOR ANTAGONIST AND DRUGS DETERMINING THE RECEPTOR BINDING ACTIVITY | NEUROCRINE BIOSCIENCES, INC. | 2002-02-19 | — | — | US | claimed |
| CN-1328559-A | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES INC (US) | 2001-12-26 | — | — | CN | claimed |
| CN-1326458-A | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES INC (US) | 2001-12-12 | — | — | CN | claimed |
| WO-2001087885-A1 | CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-11-22 | — | — | WO | claimed |
| EP-1129096-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2001-09-05 | — | — | EP | claimed |
| EP-1129091-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000027846-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-2000027850-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | UHRF1 4640/4885 |
| US-20040235871-A1 | Crf receptor antagonists | CRHR1, CRHR2, CRH | UHRF1 3624/4885 |
| US-20040229879-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, MC2R, CRHR2 | UHRF1 3958/4885 |
| US-20040242623-A1 | Chemical compounds | CYP2D6, CYP2C9, CYP3A43 | UHRF1 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.